agilon health (AGL) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $1.04
- EPS estimate
- $0.12
- EPS surprise
- +790.41%
- Revenue surprise
- +2.90%
- Revenue
- $1.5B
- Revenue estimate
- $1.5B
- Reported
- Aug 5, 2026
Agilon Health reported Q2 2026 results on August 5, 2026. Earnings per share were $1.04, far above the $0.12 estimate, a surprise of 790.41%. Revenue was $1.5 billion, 2.90% above a consensus that also rounds to $1.5 billion. A year earlier, Q2 2025 showed a loss of $6.25 per share on revenue of $1.4 billion.
Q2 2026 was the second profitable quarter in a row, after $2.94 per share in Q1 2026, the high in the table. Before that, profits came only in first quarters; 14 of the 20 quarters shown were losses. Complete years were losses of $6.43 per share in 2022, $12.25 in 2023 and $15.25 in 2024. The table lists an unusually large loss of $287.50 per share for Q4 2025, against a $6.80 estimate, far out of line with every other quarter. Revenue grew from $458.6 million in Q3 2021 to between $1.4 billion and $1.6 billion a quarter since Q1 2024. Agilon beat the EPS estimate in 7 of the 20 quarters.
Agilon reported Q3 between October 28 and November 7 in each of the past five years. That points to late October or early November 2026 for the next report.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $0.12 | $1.04 | +790.41% | $1.5B | SEC |
| Q1 2026 | May 6, 2026 | $1.04 | $2.94 | +182.56% | $1.4B | SEC |
| Q4 2025 | Feb 25, 2026 | −$6.80 | −$287.50 | −4129.68% | $1.6B | SEC |
| Q3 2025 | Nov 4, 2025 | −$3.73 | −$6.75 | −80.73% | $1.4B | SEC |
| Q2 2025 | Aug 4, 2025 | −$2.73 | −$6.25 | −128.94% | $1.4B | SEC |
| Q1 2025 | May 6, 2025 | −$0.07 | $0.73 | +1082.98% | $1.5B | SEC |
| Q4 2024 | Feb 25, 2025 | −$5.42 | −$6.50 | −19.85% | $1.5B | SEC |
| Q3 2024 | Nov 7, 2024 | −$2.46 | −$7.25 | −194.14% | $1.5B | SEC |
| Q2 2024 | Aug 6, 2024 | −$1.76 | −$1.75 | +0.43% | $1.5B | SEC |
| Q1 2024 | May 7, 2024 | −$0.32 | $0.25 | +178.99% | $1.6B | SEC |
| Q4 2023 | Feb 27, 2024 | −$6.92 | −$10.25 | −48.03% | $1.1B | SEC |
| Q3 2023 | Nov 2, 2023 | −$1.36 | −$2.00 | −47.23% | $1.2B | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.46 | −$1.00 | −119.01% | $1.1B | SEC |
| Q1 2023 | May 9, 2023 | $0.88 | $1.00 | +14.29% | $1.1B | SEC |
| Q4 2022 | Mar 1, 2023 | −$2.43 | −$3.50 | −44.12% | $689.8M | SEC |
| Q3 2022 | Nov 3, 2022 | −$1.13 | −$1.75 | −55.31% | $695.0M | SEC |
| Q2 2022 | Aug 4, 2022 | −$0.42 | −$1.25 | −198.40% | $670.1M | SEC |
| Q1 2022 | May 5, 2022 | −$0.02 | $0.07 | +576.97% | $653.4M | SEC |
| Q4 2021 | Mar 3, 2022 | −$2.64 | −$3.50 | −32.72% | $462.9M | SEC |
| Q3 2021 | Oct 28, 2021 | −$2.13 | −$2.25 | −5.88% | $458.6M | SEC |
Quarterly revenue
Frequently asked questions
When did agilon health (AGL) last report earnings?
agilon health last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did AGL beat earnings estimates?
Yes. agilon health reported EPS of $1.04 for Q2 2026 against a $0.12 estimate — a 790.41% beat.
How much revenue did AGL report last quarter?
agilon health reported $1.5B in revenue for Q2 2026, against a consensus estimate of $1.5B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.